Crestor

AstraZeneca PLC 13 February 2003 AstraZeneca Submits Information Amendment For CRESTOR(R)(rosuvastatin calcium) NDA to FDA AstraZeneca announced today the submission of an information amendment to its New Drug Application (NDA) for CRESTOR(R) (rosuvastatin calcium) Tablets in response to the US Food and Drug Administration (FDA) approvable letter of May 2002. The additional data provide further support for the proposed use of CRESTOR(R) Tablets for the treatment of patients for the management of hypercholesterolaemia, mixed dyslipidaemia and isolated hypertriglyceridaemia. 13 February 2003 Media Enquiries: Emily Denney, Tel: +44 (0) 207 304 5034 Steve Brown, Tel: +44 (0) 207 304 5033 Investor Relations: Mina Blair Robinson, Tel: +44 (0) 207 304 5084 Jonathan Hunt, Tel: +44 (0) 207 304 5087 -Ends- This information is provided by RNS The company news service from the London Stock Exchange

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings